For Investment:
a US-based startup company, which has an in-house chip manufacturing facility in Lebanon and a biology lab in the UK, offering accurate preclinical drug testing for medications developed before reaching human trials. Today, it takes pharmaceutical companies \$2.6 billion and 12 years to develop a single drug, largely because 90% of drugs fail during the late and costly clinical trial phases.
This startup’s testing solution aims to reduce that cost by half by identifying failed medications before they reach human testing.
The company has patented and developed a unique technology that enables the accurate growth of living 3D human micro-organs and diseases inside small chips—mimicking how organs grow in the human body.
These micro-organs are then used to test and reliably determine drug success or failure in the lab, prior to clinical trials.
It is a company presently pre-revenue and aims to sell its services in 2025 to pharma.
Requested Price: 600,000 US Dollars.
